These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12796809)

  • 1. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
    Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
    Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
    Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
    Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
    Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity.
    Yang ZM; Li EM; Lai BC; Wang YL; Si LS
    Biochem Cell Biol; 2007 Apr; 85(2):196-202. PubMed ID: 17534400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
    Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
    Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells.
    Liao KW; Lo YC; Roffler SR
    Gene Ther; 2000 Feb; 7(4):339-47. PubMed ID: 10694815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
    Müller D; Frey K; Kontermann RE
    J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.